Radial has launched with $50 million in venture funding to expand access to advanced mental health treatments, including neuromodulation such as accelerated transcranial magnetic stimulation and rapid-acting medications such as Spravato. General Catalyst led the Series A round, with additional backing from Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital, and Diede van Lamoen.
The company is positioning itself around a shift in psychiatry toward interventional, brain-based care that can deliver results in days to weeks rather than prolonged trial and error. Radial cited evidence that newer approaches can produce significantly improved outcomes for patients with mental health conditions, including published findings showing remission rates as high as 78% in some studies, while emphasizing that the broader healthcare delivery model has not been built to support episodic interventional care at scale.
Radial’s strategy is to build the clinical and operational infrastructure that enables these treatments to be delivered consistently, measured rigorously, and reimbursed reliably. The company said it is developing reimbursement tools and decision support designed around modern brain medicine, aiming to help clinicians focus on care delivery while giving payers more precise outcomes data to support coverage decisions. Radial also plans to address what it described as gaps in clinical decision support and operational tooling that can slow adoption of advanced treatments across everyday practice.
A core component of the rollout is a national clinic network that accepts most major insurance plans. Radial said its clinics are set up to accept Medicare, Tricare, VA CCN, Aetna, Cigna, United, and many Blue plans, to make high-impact treatment combinations available beyond cash-pay models and limited specialty access. The company framed this approach as a benefit to patients seeking faster symptom relief, providers seeking more practical workflows, and payers seeking better outcomes and lower long-term costs for complex cases.
Radial currently operates seven clinics across six states, supported by a proprietary software platform. The company said the new funding will support national expansion in 2026, including growth of both its clinic footprint and technology partnerships as it scales its model for interventional mental health care.
KEY QUOTES:
“People who are struggling with mental health can’t wait years to see if something might help through trial and error. New rapid-acting treatments work in days or weeks instead of years. We’re seeing remission rates for depression of 50-60% and as high as 78% in some studies our team has co-authored. The healthcare system hasn’t caught up. Radial is here to change that. When we have tools for the right clinical workflows and insurance pathways, people can access therapies that help them get better far sooner. It’s a dramatic difference for individuals, for families, and for the health system that ends up carrying the cost when care drags on without results.”
John Capecelatro, CEO and Co-Founder of Radial
“Psychiatry is undergoing a transformation, but most of that progress hasn’t reached patients. The science is there, yet the infrastructure to deliver modern, brain-based treatments at scale is still missing. Radial understands both the clinical evidence and the operational complexity required to close that gap. We believe this work can meaningfully expand access to effective mental health care.”
Reva Nohria, Partner at General Catalyst
“In research, we’ve proven that these powerful treatments work. They change lives. The hard part has always been bringing them into everyday clinical practice. Radial was built to close that gap. We’re taking what we know from years of clinical research and turning it into care that any patient can access. Radial is focused on the care patients have long deserved.”
Owen Muir, Chief Medical Officer at Radial
